Company Overview and News
Over the last few years, an improving domestic economy and rising demand for residential mortgages have favored the U.S. savings and loan industry. Rising income of Americans, along with relatively low interest rates, has supported the housing market by enhancing demand for residential mortgages. This has helped the industry grow over this period. In fact, lesser regulatory supervision and an improving housing market, though at a slow pace, are anticipated to keep driving the industry’s growth in the upcoming quarters too.
BANR GSBC FDEF RVSB RVSP NWBI
Investors looking for stocks in the Financial - Savings and Loan sector might want to consider either Banner (BANR - Free Report) or Heritage Financial (HFWA - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Chicago, IL –August 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Banner Corporation (BANR - Free Report) , Amazon.com, Inc. (AMZN - Free Report) , BJ's Restaurants, Inc. (BJRI - Free Report) , athenahealth, Inc.
BANR AMZN BJRI ATHN BIG BEAT
Investors interested in Financial - Savings and Loan stocks are likely familiar with Banner (BANR - Free Report) and Heritage Financial (HFWA - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
2018-08-07 zacks - 1
New York Community Bancorp (NYCB - Free Report) is poised to benefit from a robust balance-sheet position. Further, improving credit quality is expected to aid its financials. However, net interest revenues have been declining despite rising rates. The company recorded impressive growth in loans and deposits over the last five years. Recently, it reported second-quarter results, per which loans and deposits grew at quarterly rates of 1.
BANR GSBC NYCB NWBI
Good morning and welcome to the Banner Corporation’s Second Quarter 2018 Conference Call and Webcast. [Operator Instructions] Please note this event is being recorded. At this time, I would like to turn the conference over to Mark Grescovich, President and Chief Executive Officer. Please go ahead, sir.
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
16h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
18h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to BANR / Banner Corp. on message board site Silicon Investor.
as of ET